A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
PD-(L)1 x VEGF bispecifics prove a big draw.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
